NCT00192764

CompletedPhase 2

High Dose CHOP in Lymphoma

Rambam Health Care Campus Source

Compare

Other study identifiers

Sponsor study identifier

RonHDCHOP.CTIL

Study Type

interventional

Reported enrollment (type unavailable)

45

Locations

1 country

Sites

1

Timeline

Study Start

December 1996

Date type not reported

This date has not been verified as actual or estimated.

Primary Completion

Not reported

Date not reported

Study Completion

September 2010

Actual (reported)

Brief Summary

The study hypothesis is that intensification of CHOP by dose escalation of the most active drugs in the combination will improve treatment outcome. Patients with diffuse large-cell lymphoma are treated by high cyclophosphamide containing CHOP. The planned dose is 3000 mg/m2 which is 4 times the atandard one. Only 4 cycles are given.

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: completed
Reported enrollment (type unavailable): 45 participants
Study completion date: September 2010
Actual (reported)
Listed locations: 1 countries · 1 sites

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

Study Start
December 1996
Date type not reported
This date has not been verified as actual or estimated.
First Submitted
September 13, 2005
Actual (reported)
First Posted
September 19, 2005
Actual (reported)
Study Completion
September 2010
Actual (reported)

Last Updated: September 22, 2010
Status Verified: September 2010
Last Update Submitted: September 21, 2010

Conditions

Non-Hodgkin's Lymphoma

Keywords

large cell lymphomaCHOPcyclophosphamidehigh-dose

Outcome Measures

Primary Outcomes (1)

Failure-free survival

Secondary Outcomes (3)

overall survival
response rate
toxicity

Interventions

high-dose cyclophosphamideDrug

Eligibility Criteria

Age18 Years - 65 Years

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

large-cell non-Hodgkin's lymphoma
IPI low-intermediate, high-intermediate and high or bulky mediastinum

Sponsors & Collaborators

Rambam Health Care Campus
Otherlead

Study Sites (1)

Department of Oncology, Rambam Medical Center

Haifa, Israel

MeSH Terms

Conditions

Lymphoma, Non-HodgkinDendritic Cell Sarcoma, Interdigitating

Interventions

Cyclophosphamide

Condition Hierarchy (Ancestors)

LymphomaNeoplasms by Histologic TypeNeoplasmsLymphoproliferative DisordersLymphatic DiseasesHemic and Lymphatic DiseasesImmunoproliferative DisordersImmune System DiseasesHistiocytic Disorders, MalignantHistiocytosis

Study Officials

Ron Epelbaum, MD
nonaffiliated
PRINCIPAL INVESTIGATOR

Study Design

Study Type: interventional
Phase: phase 2
Allocation: NON RANDOMIZED
Masking: NONE
Purpose: TREATMENT
Intervention Model: SINGLE GROUP
Sponsor Type: OTHER

Study Record Dates

First Submitted

September 13, 2005

First Posted

September 19, 2005

Study Start

December 1996

Date type not reported

This date has not been verified as actual or estimated.

Study Completion

September 2010

Actual (reported)

NCT00003501

Antineoplaston Therapy in Treating Patients With High-Grade Stage II - Stage IV Non-Hodgkin's Lymphoma

Phase 2Terminated

NCT01998893

A Study of MabThera/Rituxan (Rituximab) in Patients With Relapsed Centroblastic Centrocytic Non-Hodgkin's Lymphoma

Phase 2Completed

NCT00003498

Antineoplaston Therapy in Treating Patients With Non-Hodgkin's Lymphoma

Phase 2Terminated

NCT01283776

Cyclophosphamide as Sole Graft-Versus-Host-Prophylaxis After Allogeneic Stem Cell Transplantation

Phase 2Completed

NCT00193479

Combination Chemotherapy and Rituximab With Pegfilgrastim Followed by Rituximab, in Large B-Cell Non-Hodgkin's Lymphoma

Phase 2Completed

NCT00989664

Pivotal Study of Iodine I 131 Tositumomab for Chemotherapy-refractory Low-grade or Transformed Low-grade B-cell Non-Hodgkin's Lymphoma

Phase 2Completed

age 18-65

You may not qualify if:

previous treatment for lymphoma
serious concurrent systemic disease

Contact the study team to confirm eligibility.

Intervention Hierarchy (Ancestors)

Phosphoramide MustardsNitrogen Mustard CompoundsMustard CompoundsHydrocarbons, HalogenatedHydrocarbonsOrganic ChemicalsPhosphoramidesOrganophosphorus Compounds

Last Updated

September 22, 2010

Record last verified: 2010-09

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT00192764
Data provider: ClinicalTrials.gov
Source updated: 2010-09-22
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:32:58 UTC

Locations

IL(1)

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (3)

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Study Officials

Study Design

Study Record Dates

You may not qualify if:

Intervention Hierarchy (Ancestors)

Source record

Locations